Skip to content

Comparison of Safety and Efficacy of Trabeculectomy with Mitomycin C versus Mitomycin C-Infused Sponges: A 6-month randomized controlled study

Comparison of Safety and Efficacy of Trabeculectomy with Mitomycin C versus Mitomycin C-Infused Sponges: A 6-month randomized controlled study

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260610005
Enrollment
80
Registered
2026-06-10
Start date
2024-09-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open-Angle Glaucoma Glaucoma Glaucoma, Open-Angle Trabeculectomy Mitomycin Intraocular Pressure Filtering Surgery Antimetabolites Randomized Controlled Trials as Topic

Interventions

Patients undergo standard trabeculectomy with intratenon Mitomycin C injection. Mitomycin C 0.2 mg/ml, 0.2 ml is mixed with 2 percent lidocaine hydrochloride, 0.2 ml, resulting in a final Mitomycin C
Experimental Procedure/Surgery,Active Comparator Procedure/Surgery
Trabeculectomy with Mitomycin C Sub-Tenon Injection,Trabeculectomy with Mitomycin C Soaked Sponge

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 years or older. 2. Diagnosed with primary open-angle glaucoma requiring trabeculectomy due to inadequate intraocular pressure control despite appropriate medical treatment. 3. Eligible for trabeculectomy with Mitomycin C augmentation. 4. Able to attend all scheduled postoperative follow-up visits for 6 months. 5. Willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Glaucoma types other than primary open-angle glaucoma, including angle-closure glaucoma, congenital glaucoma, juvenile glaucoma, neovascular glaucoma, and uveitic glaucoma. 2. Previous glaucoma surgery in the study eye. 3. Previous ocular surgery that may influence trabeculectomy outcomes, including filtering surgery or tube shunt implantation. 4. Ocular conditions that may interfere with outcome assessment, including corneal opacity affecting intraocular pressure measurement, active ocular infection, ocular inflammation, or severe ocular surface disease. 5. Severe uncontrolled systemic disease that may impair wound healing. 6. Inability or unwillingness to comply with follow-up visits or a high likelihood of loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Intraocular Pressure 6 months after surgery Mean intraocular pressure measured in mmHg using Goldmann applanation tonometry

Secondary

MeasureTime frame
Number of Glaucoma Medications 1 week, 1 month, 3 months, and 6 months after surgery Number of intraocular pressure lowering medications used after surgery,Filtering Bleb Morphology 1 week, 1 month, 3 months, and 6 months after surgery Bleb height, extent, vascularity, and Seidel test assessed using the Indiana Bleb Appearance Grading Scale,Visual Acuity 1 week, 1 month, 3 months, and 6 months after surgery Best corrected visual acuity assessed by standard ophthalmic examination,Postoperative Complications Within 1 month after surgery Incidence of hypotony, bleb leak, thin avascular bleb, and bleb related infection,Postoperative Interventions Within 6 months after surgery Frequency of postoperative interventions including laser suture lysis, bleb needling, bleb revision, and other additional procedures,Surgical Success 1 month, 3 months, and 6 months after surgery Complete success, qualified success, and surgical failure based on predefined intraocular pressure control criteria

Countries

Thailand

Contacts

Public ContactPattana Poopattanakul

Somdejphrajaotaksinmaharaj Hospital

inzxinzx@gmail.com0651935156

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026